Drug Expenditure and New Drug Introductions
Authors:
- 1 September 1993
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 4 (3) , 215-225
Abstract
This article measures the impact of the switch to new and more expensive drugs on the aggregate drug expenditure (both prescription and nonprescription) in Sweden during the period 1974 to 1991, and also on the disaggregated expenditure for 3 medical areas: asthma, hypertension and peptic ulcer disease. During the period studied, nominal drug expenditure increased 6-fold. The retail price index of drugs and the number of prescribed drugs accounted for 51.6 and 5.8% of this increase, respectively. The remaining residual amount accounted for 42.6%. Since the price index of drugs increased more slowly than the overall net price index of goods and services, the relative price of drugs decreased dramatically by about 30%. This means that increases in prices of drugs cannot explain the increase in real inflation-adjusted drug expenditure. We also show that the residual increase can be partly explained by the introduction of new and more expensive drugs. It is therefore argued that economic evaluations which compare the extra costs induced by new drugs with the extra benefits should be undertaken to guide decisions about the prescription of new and more expensive drugs.Keywords
This publication has 9 references indexed in Scilit:
- Economic Evaluation of Drug TherapyPharmacoEconomics, 1992
- Principles of Pharmacoeconomic Analysis of Drug TherapyPharmacoEconomics, 1992
- The effects of cimetidine on the cost of ulcer disease in SwedenSocial Science & Medicine, 1991
- Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study.Hypertension, 1991
- Economic evaluation in health care: Is there a role for cost-benefit analysis?Health Policy, 1991
- The Costs of Treating Hypertension in SwedenScandinavian Journal of Primary Health Care, 1991
- ADVANTAGES OF HIGH-DOSE INHALED BUDESONIDEThe Lancet, 1988
- [High-dosage inhalation steroids in asthma--analysis of costs and use in health care].1984
- A Guide to Benefit-Cost Analysis, as Seen Through a Controlled Experiment in Treating the Mentally IllJournal of Health Politics, Policy and Law, 1983